Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and/or targeted therapy: The VACANCE study

Annals of Oncology

Volumn 23, Issue 2, 2012, Pages 450-457

  Rousseau, B ^a   Loulergue, P ^b   Mir, O ^c   Krivine, A ^b   Kotti, S ^a   Viel, E ^a   Simon, T ^a   De gramont, A ^a   Goldwasser, F ^c   Launay, O ^b   Tournigand, C ^a  

^a HÔPITAL SAINT ANTOINE   (France)

^b Inserm CIC BT505 ^*  (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Adjuvant; Cancer; Chemotherapy; Influenza; Pandemic vaccine; Targeted therapies

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; HEMAGGLUTINATION INHIBITING ANTIBODY; IFOSFAMIDE; INFLUENZA VACCINE; IRINOTECAN; LAPATINIB; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEMETREXED; SUNITINIB; TRASTUZUMAB;

2009 H1N1 INFLUENZA; ADULT; AGED; ANTIBODY TITER; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CARCINOSARCOMA; CHILL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FEVER; DRUG MEGADOSE; DRUG SAFETY; DUODENUM CANCER; ERYTHEMA; ESOPHAGUS CANCER; FATIGUE; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IMMUNOGENICITY; INFLUENZA VACCINATION; INJECTION SITE PAIN; KIDNEY CANCER; LEIOMYOSARCOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; MYALGIA; NEUROENDOCRINE TUMOR; OPEN STUDY; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTECTION; PRURITUS; RECTUM CANCER; SEROCONVERSION; SINGLE DRUG DOSE; STOMACH CANCER; SWELLING; SYSTEMIC DISEASE; UNSPECIFIED SIDE EFFECT; VATER PAPILLA TUMOR;

EID: 84255211160     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr141     Document Type: Article

References (17)

1. Cooksley CD, Avritscher EB, Bekele BN et al. Epidemiology and outcomes of serious influenza-related infections in the cancer population. Cancer 2005; 104: 618-628.
2. Demicheli V, Jefferson T, Rivetti D, Deeks J. Prevention and early treatment of influenza in healthy adults. Vaccine 2000; 18: 957-1030.
3. Pollyea DA, Brown JM, Horning SJ. Utility of influenza vaccination for oncology patients. J Clin Oncol 2010; 28: 2481-2490.
4. Loulergue P, Mir O, Alexandre J et al. Low influenza vaccination rate among patients receiving chemotherapy for cancer. Ann Oncol 2008; 19: 1658.
5. Ortbals DW, Liebhaber H, Presant CA et al. Influenza immunization of adult patients with malignant diseases. Ann Intern Med 1977; 87: 552-557.
6. Haut Conseil de Santé Publique. Actualisation de l'avis relatif aux recommandations sur l'utilisation des vaccins pandé miques dirigé s contre le virus grippal A(H1N1)v. 2009; www.hcsp.fr/docspdf/./hcspa20091028_H1N1.pdf (2 October 2009, date last accessed).
7. Kendal A, Pereira M, Skehel J. Concepts and Procedures for Laboratory-Based Influenza Surveillance. Atlanta, GA: Centres for Disease Control 1982.
8. European Agency for the Evaluation of Medicinal Products. European Committee for Proprietary Medicinal Products. Guideline on influenza vaccine prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier context (EMEA/CHMP/VWP/263499/2006).6 2007.
9. Roman F, Vaman T, Gerlach B et al. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03Aadjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 2010; 28: 1740-1745.
10. Rousseau B, Chibaudel B, Bachet JB et al. Stage II and stage III colon cancer: treatment advances and future directions. Cancer J 2010; 16: 202-209.
11. Cunningham D, Atkin W, Lenz HJ et al. Colorectal cancer. Lancet 2010; 375: 1030-1047.
12. Sambhara S, McElhaney JE. Immunosenescence and influenza vaccine efficacy. Curr Top Microbiol Immunol 2009; 333: 413-429.
13. Ring A, Marx G, Steer C, Harper P. Influenza vaccination and chemotherapy: a shot in the dark? Support Care Cancer 2002; 10: 462-465.
14. van Assen S, Holvast A, Benne CA et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2010; 62: 75-81.
15. Johnson B, Osada T, Clay T et al. Physiology and therapeutics of vascular endothelial growth factor in tumor immunosuppression. Curr Mol Med 2009; 9: 702-707.
16. Kato A, Schleimer RP. Beyond inflammation: airway epithelial cells are at the interface of innate and adaptive immunity. Curr Opin Immunol 2007; 19: 711-720.
17. Weichhart T, Saemann MD. The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications. Ann Rheum Dis 2008; 67 (Suppl 3): iii70-iii74.